Zilganersen (Zanvastro), an intrathecal antisense oligonucleotide that reduces production of glial fibrillary acidic protein, became the first FDA-approved treatment for Alexander disease on September 3, 2026, after a pivotal phase 1 to 3 study reported in Neurology showed a 33.3% adjusted advantage in gait speed at week 61 with the 50 mg dose compared with control. The randomized portion enrolled 49 children and adults with this ultra-rare neurological disorder, and the FDA also considered an open-label substudy of four children younger than 2 years when extending the indication across pediatric and adult patients.
Alexander disease is driven by abnormal GFAP accumulation in astrocytes
Alexander disease is a rare, progressive neurological disorder caused by pathogenic variants in the gene encoding glial fibrillary acidic protein (GFAP), a structural protein expressed in astrocytes. When abnormal GFAP accumulates in these supportive brain cells, it disrupts nervous-system function and can lead to seizures, developmental regression, muscle weakness, gait impairment, swallowing problems, and increased intracranial pressure. The FDA estimates that the disease affects fewer than 1 in 1 million people.
The approval is notable within the broader field of rare-disease genetic medicine because the therapy is designed around the molecular cause of the disorder rather than symptom control alone. That strategy is conceptually related to other forms of gene-directed medicine, although zilganersen does not edit DNA.
Zilganersen lowers the RNA message used to make GFAP
Zilganersen is an antisense oligonucleotide, a short synthetic strand of nucleic acid designed to bind the RNA transcript that carries instructions for producing GFAP. Binding reduces the amount of GFAP protein made before it can accumulate in astrocytes. In the pivotal study, plasma GFAP fell by 33.6% with the 50 mg dose relative to control, providing evidence that the drug engaged its intended biological target.
The approved treatment is delivered by intrathecal injection into the spinal canal every three months by a trained healthcare professional. That route allows the drug to reach the central nervous system directly. It also means the treatment carries procedure-related burdens that are different from an oral or intravenous medicine.
The pivotal study found better preservation of walking speed at 61 weeks
The pivotal global study, NCT04849741, randomized 49 participants with Alexander disease during the double-blind period. The median age was 11 years, with participants ranging from 2 to 53 years. Twenty-four participants received zilganersen 50 mg, eight received 25 mg, and 17 were assigned to control.
The primary endpoint was the percent change from baseline in gait speed on the 10-meter walk test at week 61. The 50 mg dose produced a least-squares mean difference of 33.3% versus control (P=0.041). The FDA described the benefit in patients aged 5 years and older who had measurable walking difficulty at baseline as significantly better walking speed compared with untreated controls.
The study also evaluated broader measures of patient and clinician impression. These generally moved in the direction of benefit, but most did not reach conventional statistical significance. Patient Global Impression of Change favored zilganersen with a nominal P=0.010, while several other secondary measures showed trends rather than definitive effects.
The FDA used different evidence for younger children
Walking speed is not an appropriate endpoint for very young children, so the FDA evaluated children aged 2 to 4 years using a broader motor assessment that included standing, walking, running, and jumping. Children treated with Zanvastro improved on that measure while children in the control group declined.
Evidence was more limited in children younger than 2 years. Only four patients in that age range received zilganersen in an open-label substudy, and there was no concurrent control group. The FDA relied on those safety observations together with pharmacokinetic modeling showing that drug exposure at the approved dose was expected to be similar to that in older children.
Aseptic meningitis is the safety issue that requires particular attention
The most common adverse reactions reported by the FDA were vomiting, back pain, cough, headache, and post-lumbar puncture syndrome. Aseptic meningitis has also occurred with zilganersen. The FDA advises patients and caregivers to contact their healthcare team if symptoms consistent with meningitis develop so that diagnostic evaluation and treatment can begin promptly.
The route of administration also matters clinically. Repeated lumbar punctures every three months can be burdensome, particularly for children and for patients with progressive motor impairment, even when the drug itself is tolerated.
What the evidence cannot yet answer
Alexander disease is extraordinarily rare, and the randomized evidence is correspondingly small. The pivotal double-blind analysis included 49 participants, which limits how precisely uncommon adverse events and subgroup effects can be estimated. The disease is also heterogeneous across age and phenotype, making it difficult to assume that the average gait result applies equally to every patient.
The evidence in children younger than 2 years is especially limited because the FDA relied on four open-label patients plus pharmacokinetic modeling rather than a randomized comparison. Longer follow-up is also needed to determine whether the motor benefit seen through 61 weeks remains durable and whether treatment changes long-term outcomes such as loss of independence, swallowing function, respiratory complications, or survival.
The pivotal study was sponsored by Ionis Pharmaceuticals, which developed and now markets Zanvastro in the United States. Industry sponsorship does not negate the randomized result, but it is relevant context when interpreting efficacy analyses and subsequent commercial claims.
The approval converts a molecular target into the first disease-directed therapy
Zanvastro is different from symptomatic neurological treatment because it reduces production of the protein that drives Alexander disease. Bites of Bio recently covered another mechanism-based neurology approval, Orzeyful for narcolepsy type 1, but zilganersen goes further upstream by targeting the RNA message generated from a disease-causing gene.
Emily Freilich, M.D., director of the FDA’s Division of Neurology I, summarized the regulatory significance: “Today’s approval is a landmark moment for this community, offering the first therapy that addresses the underlying cause of this rare and serious disease.”
References
- Waldman A, Lynch D, Tonduti D, et al. Efficacy and Safety of Zilganersen, an Investigational RNA-targeted Antisense Therapy, in People Living with Alexander Disease: Results from a Pivotal Study. Neurology. 2026;106(11_Supplement_1):941. DOI: 10.1212/WNL.0000000000213207.
- U.S. Food and Drug Administration. FDA Approves First Drug to Treat Alexander Disease. September 3, 2026. FDA press announcement.